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Suppression of Helicobacter pylori reduces gastrin
releasing peptide stimulated gastrin release in
duodenal ulcer patients
K Beardshall, S Moss, J Gill, S Levi, P Ghosh, R J Playford, J Calam
Abstract
Helicobacterpylori increases gastrin release in
duodenal ulcer patients. This may be through
disruption or changes in the mucus layer
affecting the access of luminal stimulants to
gastrin releasing cells. The effect of suppress-
ingH pylon on gastrin release stimulated by a
non-luminal stimulus, gastrin releasing peptide
(GRP), was examined. Eleven patients with
active duodenal ulcer disease and colonised
withH pylori received an intravenous infusion
of GRP (2.9 pmollkg/minute for 30 minutes)
and the plasma gastrin response was measured.
Basal and peak pentagastrin stimulated acid
output were also determined. Patients were
treated with tripotassium dicitratobismuthate
(De-Nol) and metronidazole to suppress
Hpylon and the tests were repeated. Suppres-
sion of H pylon decreased plasma gastrin
concentrations during GRP infusion, but acid
output was not affected. Chromatographic
analysis of the forms of gastrin in plasma
showed a significant fail in gastrin 17, the
predominant form found in the gastric antrum.
Gastrin 34 did not fall significantly. This study
shows that suppression ofH pylon decreases
the hypergastrinaemia caused by the non-
luminal stimulant, GRP, mainly via decreasing
gastrin 17.
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Duodenal ulcer disease is strongly associated
with gastric colonisation with Helicobacter
pylori.A We reported that H pylori increases
release of the antral hormone gastrin in these
patients.56 This may explain the raised post-
prandial gastrin release7 and gastric acid secretion
seen in duodenal ulcer disease.8'10 Several
mechanisms have been proposed to explain how
H pylon increases gastrin release. H pylori may
specifically increase gastrin release in response to
luminal stimulants. For example, either dis-
ruption" or alkalinisation'2 of the gastric mucus
layer by H pylori could increase the access of
luminal stimulants to gastrin releasing cells.
Patients with hypergastrinaemic duodenal ulcer
disease have increased sensitivity to luminal
stimulants of gastrin release'3 and so far studies
of the effects ofH pylori on gastrin release have
used only food as the stimulus,56'4 and this
stimulates gastrin 17 predominantly.'5 We there-
fore examined the effect of suppressing H pylon
on the release ofgastrin stimulated by intravenous
infusions of the non-luminal stimulant gastrin
releasing peptide (GRP) - a peptide that is
normally present in nerve fibres within the
gastric antrum.|6. We also studied the mole-
cular forms of the plasma gastrin response to
GRP to determine whether this was affected by
H pylori colonisation.
Methods
The study was approved by the local ethics
committee and all patients gave informed con-
sent. Eleven patients, three women and eight
men aged 27-60 years (mean 43), took part.
They all had active duodenal ulcer disease and a
positive biopsy urease test forH pylon on entry.
Histological examination of antral biopsy speci-
mens stained with haematoxylin and eosin
showedH pylori like organisms in all cases.
Within one week of endoscopy, when the
patients had been off all therapy for at least four
days, they were given a standard test of gastric
acid output using stimulation by pentagastrin
infusion with correction for pyloric losses, as
described previously.58 They also received an
intravenous infusion of GRP (Cambridge
Research Biochemicals, Cambridge, UK),
2.9 pmol/kg/minute for 30 minutes, and blood
samples were collected for gastrin assay at the
times shown in Figure 1.
Patients then received tripotassium dicitrato-
bismuthate (De-Nol tabs) 120mg four times daily
for four weeks, with metronidazole 400 mg four
times daily for the first two weeks of treatment.
Endoscopy was repeated within one week of
completing this therapy, and the studies of
pentagastrin stimulated acid output and GRP
stimulated gastrin release were repeated within
one week of endoscopy.
Blood for gastrin assay was collected into
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Figure 1: Median plasma gastrin concentrations (pmolll)
during iv gastrin releasing peptide infusion (2-9 pmollkgl
minute) before (-*--) and after (----0----) treatment to
suppress Helicobacter pylori. *p<OO5, tp<O0O1,
tp<O OO5.
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Figure 2: Gastrin immunoreactivity elutingfrom Sephadex
G50 chromatography column of 1 ml plasma before (-) and
after (----) treatment. A representative patient. G] 7=gastrin
17; G34=gastrin 34.
chilled tubes containing disodium EDTA (2 mg/
ml of blood). Plasma was separated promptly
and stored at -20°C until further analysis.
Gastrin was measured in plasma samples by
radioimmunoassay using antibody G179, pro-
vided by Professor Bloom.' Plasma samples with
the highest GRP stimulated gastrin concentra-
tions for each patient were further analysed by
chromatography on 1xl100 cm Sephadex G50
superfine columns (Pharmacia, Uppsala,
Sweden), eluted with 0.05 mol/l ammonium
bicarbonate containing 0.05% sodium azide,
pH 8-4, at 4°C and 0-2 ml/minute. Eluates were
dried by centrifugal evaporation (Savant, Farm-
ingdale, NY, USA) in the assay tubes before
gastrin radioimmunoassay.
Statistical analysis was by Wilcoxon's matched
pairs test.
Results
PLASMA GASTRIN CONCENTRATIONS
Median plasma gastrin concentrations during
infusion of GRP were significantly lower after
the anti-H pylori treatment at most time points.
(Fig 1). A biphasic gastrin response to the GRP
infusion is evident. The integrated plasma gastrin
response was also significantly lower after treat-
ment. Before treatment the median integrated
gastrin response was 1007 (range 312-3579)
pmol.min/l, this fell to 429 (153-1903) after
treatment, p<001.
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Figure 3: Peak pentagastrin stimulated gastric acid output
before and after treatment.
CHROMATOGRAPHY OF FORMS
Gastrin immunoreactivity eluted from the gel
filtration columns in two peaks corresponding to
gastrin 34 and gastrin 17 (Fig 2). After suppres-
sion of H pylori there was a significant fall in
gastrin 17 from a median of 30 (range 4-207) to 5
(1-24) pmol/l, p<001. Gastrin 34 fell to a lesser
extent, from a median of 8 (2-65) to 4 (2-6)
pmol/l but the change in this form did not reach
statistical significance.
GASTRIC ACID SECRETION
Basal acid output and peak pentagastrin stimu-
lated acid output were not significantly affected
one month after the start oftreatment to suppress
H pylori (Fig 3). Median basal acid output was
3.7 (range 0.3-26.5) mEq/hour before treatment
and 2.9 (0-7-13-9 (mEq/hour afterwards. Median
peak acid outputs were 37.4 (209-61 3) and 36.5
(23.6-53.0) mEq/hour before and after treat-
ment respectively.
Discussion
In this study we have shown for the first time that
suppression of H pylori by De-Nol and metro-
nidazole leads to a fall in the release of gastrin
stimulated by a non-luminal stimulus. This
stimulant was GRP, which is present in nerve
fibres in the gastric antrum'"'8 and is capable of
stimulating gastrin release at very low doses.'9
GRP is closely related to the frog skin peptide,
bombesin, and therefore gastric colonisation
with H pylon' may be responsible for the in-
creased gastrin response to bombesin in patients
with duodenal ulcer disease.20
The finding of enhanced GRP stimulated
gastrin release in duodenal ulcer disease does not
support the idea that H pylori increases gastrin
release purely by enhancing access of luminal
stimulants to gastrin releasing cells, either
through disruption" or alkalinisation' of the
mucus layer.
There are alternative explanations for the
phenomenon. Firstly, H pylon' might increase
gastrin release through its urease enzyme releas-
ing alkaline ammonia, raising the pH within the
antral mucus layer and thus preventing inhibition
of gastrin release by low intraluminal pH.' We
are not aware of any studies of the effect of GRP
(or bombesin) on gastrin release in patients with
chronically raised intragastric pH, but these
patients have increased gastrin responses to
other stimuli, including food ' and calcium in-
fusion,22 suggesting that chronic alkalinisation of
the antrum by H pylon' might also increase. the
response to GRP. Secondly, it has been suggested
thatH pylori increases gastrin release by causing
local inflammation, since basal gastrin concen-
trations are raised in patients with non-H pylon'
antritis,23 and the cytokines y interferon and
interleukin-2 stimulate gastrin release from the
isolated perfused dog antrum."4 There have been
no studies of this putative effect of inflammation
on the release of gastrin by various stimulants. If
inflammation does indeed increase the release of
gastrin it might be expected that the effect would
be non-specific and would include the response
to GRP.
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De-Nol has a number of effects on gastric
physiology apart from its anti-H pylort effect.
These include stimulating prostaglandin syn-
thesis, increasing gastric mucus secretion, and
coating the ulcer crater.25 It is therefore possible
that the changes in gastrin observed after treat-
ment may not be related to suppressing H pylori
at all, though this remains the most likely
explanation.
The study of the effect of suppression of H
pylon on the different circulating forms ofgastrin
was undertaken because gastrin 34 is the pre-
dominant form in the duodenum whereas antral
gastrin is mainly in the form of gastrin 17.26 Since
H pylori has been regarded as a stimulant of
antral gastrin release,' clearance of H pylon
might be expected to affect gastrin 17 more than
gastrin 34. Our results indicate that this is the
case - gastrin 17 fell significantly after treatment
whereas the fall in gastrin 34 was less marked.
The lack of effect of suppression ofH pylort on
basal and peak acid output over a four week
period is consistent with the findings of our
previous study.6 It remains to be seen whether
prolonged absence of the organism eventually
leads to a fall in peak acid output, which is a
measure of the parietal cell mass, due to with-
drawal of the trophic effect of gastrin.27 Results
obtained by McColl show that in the short term
clearance ofHpylon reduces postprandial gastric
acidity,'4 which is dependent on the stimulation
of acid secretion by gastrin.2529
Further studies are required to determine the
mechanism by which H pylon7 increases human
gastrin release.
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